Ads
related to: metastatic urothelial cancer survival- Financial Support
Find Info On Financial Support
For Eligible Patients. Learn More.
- Safety Information
Important Safety Info And More
On The Official Patient Site.
- Resources & Support
For Patient And Caregiver
Learn More.
- FAQs
Find FAQs For This Treatment Option
On The Official Patient Site.
- Financial Support
Search results
Results from the WOW.Com Content Network
In May 2016, the FDA granted accelerated approval to atezolizumab for locally advanced or metastatic urothelial carcinoma treatment after failure of cisplatin-based chemotherapy. [18] The confirmatory trial (to convert the accelerated approval into a full approval) failed to achieve its primary endpoint of overall survival. [19]
The most common histology seen in primary urethral cancer (a cancer which originates in the urethra, as opposed to cancer cells from elsewhere in the body which metastasize to the area) is urothelium, a type of transitional epithelium. Urothelial cell cancers comprise just over half of primary urethral cancers.
Bladder tumors are classified by their appearance under the microscope, and by their cell type of origin. Over 90% of bladder tumors arise from the cells that form the bladder's inner lining, called urothelial cells or transitional cells; the tumor is then classified as urothelial cancer or transitional cell cancer.
In January 2024, the FDA approved erdafitinib for adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy. [12]
Invasive urothelial carcinoma is a type of transitional cell carcinoma. It is a type of cancer that develops in the urinary system: the kidney , urinary bladder , and accessory organs. Transitional cell carcinoma is the most common type of bladder cancer and cancer of the ureter , urethra , renal pelvis , the ureters , the bladder , and parts ...
PINX1 levels were found to be reduced in urothelial carcinoma of the bladder (UCB) compared to normal urothelial bladder epithelium. “PINX1 levels were inversely correlated with tumor multiplicity, advanced N classification , high proliferation index, and poor survival.” [ 15 ] Over-expression of PINX1 reduced UCB cell proliferation and G1 ...
TALZENNA in combination with XTANDI demonstrated statistically significant overall survival benefit in patients with metastatic castration-resistant prostate cancer becoming the first and only ...
Sacituzumab govitecan, sold under the brand name Trodelvy by Gilead Sciences, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. [9] [11] [12] [13]
Ads
related to: metastatic urothelial cancer survival